EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

VEXAS syndrome: a Swiss national retrospective cohort study

Louis Wolff, Leo Caratsch, Fabian Lötscher, Luca Seitz, Pascal Seitz, Yann Coattrenec, Jörg Seebach, Oliver Vilinovszki, Stefan Balabanov, Jakob Nilsson, Aylin Canbek, Aurélie Clottu und 10 weitere

Swiss Medical Weekly · 2024

DOI: 10.57187/s.3879 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Swiss Medical Weekly, 2024. Verfasst von Louis Wolff und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland. Hauptthemen laut MEDLINE: Ubiquitin-Activating Enzymes, Hereditary Autoinflammatory Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

STUDY AIMS: VEXAS syndrome is a recently discovered monogenic auto-inflammatory disease caused by a somatic mutation in the UBA1 gene that manifests with rheumatologic and haematologic features. In this report, we present the first Swiss cohort, detailing its manifestations and treatment outcomes among Swiss patients. METHODS: Data were retrospectively collected from nine hospitals across Switzerland, representing a broad geographic distribution. Treating physicians completed a standardised case report form for each patient. The principal investigator and the co-investigators collected and analysed all case report forms. RESULTS: We identified 23 patients between July 2022 and 2023, of which 17 are described. All were male. They presented with skin manifestations (88%), general symptoms (82%), venous thromboembolism (59%), ocular manifestation (59%), lung infiltrates (59%) and articular manifestations (47%). Central nervous system and kidney manifestations were very rare, and heart and digestive manifestations were absent. Macrocytic anaemia was present in all patients throughout the disease progression but only in two-thirds of patients (12/17, 71%) at the time of diagnosis. Clinical response was reached in all cases treated with ruxolitinib (4/4, 100%), upadacitinib (1/1, 100%), azacytidine (5/5, 100%) and haematopoietic stem cell transplantation (2/2, 100%). All deaths were attributed to infections (5/5, 100%). CONCLUSION: This study corroborates the clinical spectrum of VEXAS syndrome described in other cohorts. It suggests that VEXAS syndrome is not limited to patients with macrocytic anaemia. In this study, azacytidine has been used effectively among patients with myelodysplastic syndrome. In addition, Janus kinase (JAK) inhibitors, particularly ruxolitinib, have been successfully used even in those without myelodysplastic syndrome. We report two successful treatments by haematopoietic stem cell transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Activating EnzymesHereditary Autoinflammatory DiseasesHumansSwitzerlandMaleRetrospective StudiesMiddle AgedAdultAgedPyrazolesMutationPyrimidinesNitrilesMyelodysplastic SyndromesSkin Diseases, Genetic

Substanzen

Ubiquitin-Activating EnzymesUBA1 protein, humanPyrazolesruxolitinibPyrimidinesNitriles

Autor:innen und Institutionen

  • Division of Immunology and Allergy, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Division of Internal Medicine, Department of Medicine, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
  • Department of Rheumatology and Immunology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Upper Valais Hospital Centre Visp (SZO), Rheumatology, Hôpital du Valais, Visp, Switzerland.
  • Division of Immunology and Allergy, Geneva University Hospitals, Geneva, Switzerland.
  • Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.

Zitieren

APA

Wolff, L., Caratsch, L., Lötscher, F., Seitz, L., Seitz, P., Coattrenec, Y., Seebach, J., Vilinovszki, O., Balabanov, S., Nilsson, J., Canbek, A., Clottu, A., Bruecker, R., Efthymiou, A., Regli, D., Chrysoula, M., Amstad, A., Bonadies, N., Blum, S., …, & Comte, D. (2024). VEXAS syndrome: a Swiss national retrospective cohort study. Swiss Medical Weekly. https://doi.org/10.57187/s.3879

Vancouver

Wolff L, Caratsch L, Lötscher F, Seitz L, Seitz P, Coattrenec Y, et al. VEXAS syndrome: a Swiss national retrospective cohort study. Swiss Medical Weekly. 2024. doi:10.57187/s.3879

BibTeX
@article{Wolff2024,
  author = {Wolff, Louis and Caratsch, Leo and Lötscher, Fabian and Seitz, Luca and Seitz, Pascal and Coattrenec, Yann and Seebach, Jörg and Vilinovszki, Oliver and Balabanov, Stefan and Nilsson, Jakob and Canbek, Aylin and Clottu, Aurélie and Bruecker, Rolf and Efthymiou, Anna and Regli, Dena and Chrysoula, Manolaraki and Amstad, Andrea and Bonadies, Nicola and Blum, Sabine and Chitic, Mariana and Schreiber, Cornelia and Comte, Denis},
  title = {VEXAS syndrome: a Swiss national retrospective cohort study},
  journal = {Swiss Medical Weekly},
  year = {2024},
  doi = {10.57187/s.3879}
}
Kostenlos starten →